Owa Shunsuke, Sasaki Takeshi, Taniguchi Akito, Omori Kazuki, Nishikawa Taketomo, Kato Momoko, Higashi Shinichiro, Sugino Yusuke, Toyomasu Yutaka, Takada Akinori, Nishikawa Kouhei, Nomoto Yoshihito, Inoue Takahiro
Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu 514-8507, Mie, Japan.
Department of Radiology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu 514-8507, Mie, Japan.
Curr Oncol. 2025 Jul 3;32(7):385. doi: 10.3390/curroncol32070385.
Radiation therapy, including external-beam radiation therapy (EBRT) and brachytherapy, is curative for localized prostate cancer. Hydrogel spacer (HS) placement between the rectum and prostate is popular for reducing radiation-related complications. Criteria to identify patients who benefit from HS placement would be clinically valuable. In a retrospective analysis of 430 patients with localized prostate cancer treated between November 2010 and March 2023 with ≥2 years of follow-up, we evaluated the incidence of rectal hemorrhage and its association with the median distance at the midpoint between the prostate and the rectum (mDPR) on pretreatment MRI. Rectal hemorrhage occurred in 6% of HS cases and 18% of non-HS cases ( < 0.001). Among 268 patients who received EBRT (±brachytherapy), the incidence was 9% with HS and 30% without HS ( < 0.001). In non-HS cases, the rate in patients with mDPR ≤ 1.62 mm was higher than in those with mDPR > 1.62 mm (24% vs. 12%, respectively; = 0.04). In patients with EBRT and mDPR ≤ 1.62 mm, HS significantly reduced hemorrhage (9% vs. 39%, respectively; < 0.001). Multivariate analysis identified mDPR and HS as independent predictors of rectal hemorrhage (both = 0.02). Thus, HS placement may be safely omitted in non-EBRT cases with mDPR ≥ 1.62 mm.
放射治疗,包括外照射放射治疗(EBRT)和近距离放射治疗,对局限性前列腺癌具有治愈作用。在直肠和前列腺之间放置水凝胶间隔物(HS)有助于减少放疗相关并发症,这一方法很受欢迎。确定能从HS放置中获益的患者的标准具有临床价值。在一项对2010年11月至2023年3月期间接受治疗且随访时间≥2年的430例局限性前列腺癌患者的回顾性分析中,我们评估了直肠出血的发生率及其与治疗前MRI上前列腺和直肠中点的中位距离(mDPR)之间的关联。HS组直肠出血发生率为6%,非HS组为18%(<0.001)。在268例接受EBRT(±近距离放射治疗)的患者中,HS组发生率为9%,无HS组为30%(<0.001)。在非HS组中,mDPR≤1.62 mm的患者发生率高于mDPR>1.62 mm的患者(分别为24%和12%;P = 0.04)。在接受EBRT且mDPR≤1.62 mm的患者中,HS显著降低了出血发生率(分别为9%和39%;P<0.001)。多变量分析确定mDPR和HS是直肠出血的独立预测因素(均P = 0.02)。因此,在mDPR≥1.62 mm的非EBRT病例中,可能可以安全地省略HS放置。